Acetyl-leucine in Post-stroke Ataxia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT07275749
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT07275749
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Recruiting
Technical summary
Registry record NCT07275749. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-01 (anticipated); primary completion 2026-07-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Acetyl-leucine in Post-stroke Ataxia
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Acetyl-Leucine
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Clopidogrel 75 Mg Oral Tablet
- Intervention (Drug)
- aspirin 100mg
- Lead sponsor
- Kafrelsheikh University
Record details
- Record id
cardio:ct-nct07275749- Content hash
edb130a6b2cdce7d8ae8c8a22495dfab640ffaaceffcdd7b7248a45f0fe912f4